Eisai publishes additional detailed analyses from lecanemab phase 2b study
Go back to Eisai publishes additional detailed analyses from lecanemab phase 2b study| BARNES GROUP, Inc. (NYSE: B) | Delayed: 36.83 +1.09 (3.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $35.74 | 52 Week High | $44.27 | |||
| Open | $36.44 | 52 Week Low | $30.07 | |||
| Day High | $36.88 | P/E | 28.11 | |||
| Day Low | $36.04 | EPS | $1.31 | |||
| Volume | 10,799,364 | |||||
| BIOAMBER, Inc. (NASDAQ: BIOA) | Delayed: 24.89 +1.26 (5.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $23.63 | 52 Week High | $8.73 | |||
| Open | $23.75 | 52 Week Low | $2.86 | |||
| Day High | $24.93 | P/E | N/A | |||
| Day Low | $23.26 | EPS | $-3.82 | |||
| Volume | 588,348 | |||||
